Abalos Therapeutics GmbH
Merowingerplatz 1 A, Bilk, 40225 Duesseldorf, Germany
About the sponsor
Abalos Therapeutics GmbH demonstrates a concentrated focus on advancing cancer immunotherapy through innovative therapeutic approaches. The company's research portfolio centers on harnessing the immune system's capacity to target and eliminate malignant cells, with particular emphasis on developing novel treatment modalities for patients with solid tumors.
- Immune checkpoint modulation
- T-cell engaging bispecific antibodies
- Tumor-targeted immunotherapy
- Advanced solid tumor treatment
The sponsor's investigational programs explore mechanisms that enhance anti-tumor immune responses, with research efforts directed toward understanding how engineered biologics can selectively activate immune effector cells against cancer. This work encompasses the development of therapeutic candidates designed to overcome tumor immune evasion and establish durable clinical responses in oncology patients.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.